cagkansayin
Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market capitalization in early trading Tuesday after Pfizer (New York Stock Exchange:PFE) decided to end a collaboration with the company for its gyroctocogene fitelparvovec gene therapy targeting the bleeding disorder hemophilia A.
Sangamo (